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Original Article

Digital Health Technology in Asthma: A
Comprehensive Scoping Review
Giselle Mosnaim, MD, MSa, Guilherme Safioti, MDb, Randall Brown, MD, MPHc, Michael DePietro, MDc,
Stanley J. Szefler, MDd, David M. Lang, MDe, Jay M. Portnoy, MDf, Don A. Bukstein, MDg, Leonard B. Bacharier, MDh,
and Rajan K. Merchant, MD, FACAAIi Evanston, Ill; West Chester, Pa; Aurora and Cleveland, Colo; Kansas City, Mo; Greenﬁeld,
Wis; Nashville, Tenn; Woodland, Calif; and Amsterdam, The Netherlands

What is already known about this topic? Digital technology provides an opportunity to improve and individualize asthma
self-management signiﬁcantly across a variety of intervention types; however, the impact of different digital intervention
characteristics has yet to be assessed.
What does this article add to our knowledge? Signiﬁcant heterogeneity exists in study designs, patient populations,
and outcomes measurement for digital interventions; more alignment is needed to measure impacts accurately on different
dimensions of care and to guide future successful interventions.
How does this study impact current management guidelines? This scoping review does not directly affect current
guidelines for asthma self-management, but it is hoped that it will inform the design of future digital intervention studies.
BACKGROUND: A variety of digital intervention approaches
have been investigated for asthma therapy during the past
decade, with different levels of interactivity and personalization
and a range of impacts on different outcome measurements.
OBJECTIVE: To assess the effectiveness of digital interventions
in asthma with regard to acceptability and outcomes and
evaluate the potential of digital initiatives for monitoring or
treating patients with asthma.
METHODS: We evaluated digital interventions using a scoping
review methodology through a literature search and review. Of
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871 articles identiﬁed, 121 were evaluated to explore
intervention characteristics, the perception and acceptability of
digital interventions to patients and physicians, and effects on
asthma outcomes. Interventions were categorized by their level
of interactivity with the patient.
RESULTS: Interventions featuring non-individualized content
sent to patients appeared capable of promoting improved
adherence to inhaled corticosteroids, but with no identiﬁed
improvement in asthma burden; and data-gathering interventions appeared to have little effect on adherence or asthma
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Abbreviations used
ACT- Asthma Control Test
HCP- Health care professional
ICS- Inhaled corticosteroids
SABA- Short-acting b-agonist
SMS- Short message service

burden. Evidence of improvement in both adherence and
patients’ impairment due to asthma were seen only with
interactive interventions involving two-way responsive patient communication. Digital interventions were generally
positively perceived by patients and physicians. Implementation was considered feasible, with certain preferences
for design and features important to drive use.
CONCLUSIONS: Digital health interventions show substantial
promise for asthma disease monitoring and personalization of
treatment. To be successful, future interventions will need to
include both inhaler device and software elements, combining
accurate measurement of clinical parameters with careful
consideration of ease of use, personalization, and patient
engagement aspects. Ó 2021 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/). (J
Allergy Clin Immunol Pract 2021;9:2377-98)
Key words: Asthma; eHealth; Connectivity; Inhalers; Adherence;
Monitoring; Disease control; Perception; Acceptability;
Feasibility

INTRODUCTION
Rationale
Asthma continues to be a signiﬁcant chronic disease burden,
with estimated patient numbers approaching 350 million globally.1 Asthma is a major source of direct and indirect economic
cost in addition to reduced quality of life and premature death in
patients of all ages, including children.2 Several areas of unmet
clinical need are associated with conventional asthma management; while medications such as inhaled short-acting b-agonists
(SABA) and inhaled corticosteroids (ICS) are efﬁcacious,
considerable long-term commitment to asthma self-management
on behalf of the patient is required for therapeutic success.
Asthma self-management includes advice and education on
self-monitoring and a deﬁned asthma management plan supported by regular professional review. Self-management is
recognized as an effective method to improve asthma control and
quality of life and reduce unscheduled consultations and hospitalizations across diverse demographic groups.3 For the patient,
adherence to medication regimens is a key element of successful
asthma management, in conjunction with wide-ranging factors
including disease perception, patient education and understanding of symptoms, comorbidities, inhaler technique, access
to medications, and health care professional (HCP) support.4 On
the part of clinicians, implementation of evidence-supported
management guidelines for assessment, monitoring, patient education, control of environmental factors, and pharmacologic
treatment is a key factor, although adherence to such guidelines
varies among different physician groups.5,6
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Several areas of asthma self-management could be improved
using digital technology, including disease disparity, medication
adherence, patienteclinician communication, personalized patient education, and passive monitoring of patient characteristics
and behaviors that could prompt timely intervention. Technological innovations have the potential to support patients with
disease self-management, allow for remote management by
health care providers, and make future asthma management
more proactive.7
Researchers have explored a variety of different digital asthma
approaches including passive education, interactive websites, and
electronic medication monitoring devices. Given the increasing
prevalence of asthma worldwide and patient dependence on
traditional inhaler devices to manage the disease, the inclusion of
more advanced technology as a part of asthma self-management
will be an essential next step to improving therapy for respiratory
diseases. Lockdown and social distancing as a result of the
COVID-19 pandemic have caused increased uptake and reliance
on videoconferencing and telemedicine in various therapy areas.8
Increased familiarity with telemedicine provides an opportunity
for remote monitoring and disease management, particularly in
areas where access to HCPs is challenging.
Given the wealth of available literature and heterogeneity of
digital technologies used to varying degrees of success, we performed a scoping review to assess the available research in this
ﬁeld. Scoping reviews provide a preliminary assessment of the
size and scope of available literature on a topic and characterize
the nature of published studies to provide an overview of large,
heterogeneous bodies of literature. Furthermore, scoping reviews
provide a platform for more precise systematic reviews to look at
speciﬁc research questions. This scoping review therefore seeks to
evaluate the different options that have been explored and assess
the future utility of digital health technology in asthma.

Objective
This study aimed to evaluate the current and potential future
usability, acceptability, uptake, effectiveness, and adoption of
digital health technology for treating or monitoring asthma using
a scoping review methodology. The potential future reach and
durability of these technologies will also be considered.
METHODS
Scoping review approach
We conducted a systematic scoping review based on the methodology described9 and the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses extension for Scoping Reviews guidelines,10 including identifying the research question, identifying
relevant studies, selecting the study, charting data, collating, and
summarizing and reporting the results. The purpose of a scoping
review is to give a broad overview of the available literature without
being directed toward a single discrete research question.

Sources and searches
We searched PubMed, Embase, and the Cochrane Library for
January 2010 to June 2019 using the search terms and criteria in
Table E1 (in this article’s Online Repository at www.jaci-inpractice.
org), adapted for each database, to identify asthma studies that
assessed the effect of digital health technology interventions on patient outcomes, including symptoms, adherence, and medication use
or therapy regimen. We also included studies that incorporated the
acceptability of digital interventions to patients and HCPs and the
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TABLE I. Classification of different intervention types
Intervention category

Intervention types

Generalized studies (not patientspeciﬁc or bidirectional):
content given to patient
Patient-speciﬁc, noninteractive
studies (unidirectional): data
collected from or sent to patient

Patient-speciﬁc interactive studies
including telehealth and video
counseling: bidirectional
interaction

 Automated/speech recognition and SMS dose and pharmacy-reﬁll reminders
 Noninteractive education or motivational coaching by telephone, text, e-mail and other digital means
(eg, simple access to static content)
 Decision support tool for randomized controlled trial enrollment
 Device monitoring: noninhaler digital parameter tracking (eg, lung function) not resulting in immediate or
ongoing asthma management feedback to patient (ie, data collection to inform health care professional at
next visit)
 Individualized static education and/or motivation
 Digital questionnaires (by SMS/Web/phone) including ecological momentary association for data collection
only (ie, not informing therapy)
 Inhaler only: data collected on device from digital inhalers or adherence monitors but not fed back to patient
for self-management
 Inhaler platform: data collected from digital inhalers and a Web or app platform but not fed back to patient
for self-management
 Platform only: online digital chat platform (by Web or mobile app) providing nonindividualized education
 Interactive education or motivational coaching
 Device monitoring: noninhaler digital parameter tracking (eg, lung function, inhaler technique) with
feedback to patient (usually by smartphone app)
 Digital inhalers with electronic adherence monitors and individualized patient feedback
 Digital inhaler studies with accompanying individualized asthma management Web or app platform
 Interactive asthma management platforms that support self-management by collecting symptoms or Asthma
Control Test/other data and give responses to guide patient’s asthma treatment
 Telemedicine interventions by phone, video, or SMS

SMS, short message service.

871 records identified through
database and manual searching

675 records excluded
•
•
•

Consensus decision by two parallel reviewers: 566
Adjudication by third author: 18
Articles met exclusion criteria: 91
(30: clinical trial registration; 3: non peer-reviewed;
13: ongoing/planned trial; 45: review article)

•

Not including digital intervention data for regular
asthma therapy: 30
Congress abstracts: 25
Duplicates/secondary publications: 12
Trial design/protocols: 8

196 articles screened and
adjudicated (title and abstract)

121 full-text articles included in
qualitative analysis
•
•
•

•

75 articles excluded
•
•
•

Generalized studies: 17
Patient-specific, unidirectional
interventions: 24
Patient-specific, bidirectional
interventions: 66
Patient perception: 14

FIGURE 1. Articles selected for analysis.

feasibility of their wider uptake. Congress abstracts were excluded
from the results. Database searches were supplemented by manual
searches and references as appropriate.
Nonrelevant articles and duplicates were excluded; the titles and
abstracts of remaining citations were reviewed by two authors (G.S.
and G.M.) in parallel; a third author (R.K.M.) adjudicated discrepancies. Full-text articles were then obtained and a second round
of screening was conducted (two reviewers worked in parallel and
adjudication was performed by a third reviewer) and further articles
were excluded as necessary. Articles were assessed for the type of

digital health technology employed, study design, size of the study,
and outcomes assessed.

Data extraction and synthesis
The full text of the selected articles was used to identify the types
of technology used. Interventions were grouped (Table I) according
to their primary characteristic (in which interventions contained
more than one aspect), speciﬁcally, according to their level of
interactivity with the patient. Interventions in which nonindividualized information was sent to patients on an automated
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FIGURE 2. Bubble plot showing relative numbers of publications for different intervention categories by year.

basis (eg, short message service (SMS)-based dose reminders and
automated pharmacy prescription reﬁll calls, or access to noninteractive, nonepatient speciﬁc digital educational material) were
termed ‘generalized studies’. Interventions in which individualized
information was gathered from or sent to patients (eg, parameter
monitoring by a device with no feedback to the patient, or provision
of patient-speciﬁc education) were termed ‘patient-speciﬁc, noninteractive studies’. Interventions composed of an interactive relationship with the patient, in which insights based on data collected
from the patient or resulting from patient behavior were fed back to
the patient to assist with asthma management on a personalized basis
(eg, an asthma management platform responding to adherence data
from a digital inhaler or questionnaire feedback from the patient)
were termed ‘patient-speciﬁc interactive studies’. Within these broad
intervention categories, studies were further grouped according to
the type of technology involved (Table I).
Details of the studies performed (eg, subject characteristics,
sample size, randomization) and outcomes, including adherence,
asthma control or impairment and health care use were captured in a
standardized table format as part of the data charting process.
Adherence outcomes were assessed for being subjective (ie, reliant on
questionnaire data or patient recollection) or objective (ie, monitored
automatically as a result of medication use, including one study that
calculated adherence from electronic medical records).
To assess the impact of the different intervention categories, we
identiﬁed studies in which a positive effect (vs no effect or a negative
effect) was reported with the intervention in three domains: adherence to ICS (and long-acting b2-agonist) therapy, impairment
caused by asthma (most commonly assessed by Asthma Control Test
[ACT] score, but including changes in symptoms and quality of life
when reported), and health care resource use (urgent consultations,
emergency department visits, or hospitalizations). Because of heterogeneity in data reporting, to include as many studies as possible in
our broad overview, we considered statistically signiﬁcant, numerical, and anecdotal reports of beneﬁt as evidence of positive effects in

each of these three domains. Counts for studies reporting positive
versus no effect or negative effects were then summarized.
Articles that reported patient and HCP perceptions of digital
technologies were assessed separately, and relevant observations were
extracted.

RESULTS
Selection of sources of evidence
Our selection process identiﬁed 121 articles for inclusion in
this scoping review (Figure 1); 17 articles described generalized
studies, 23 described patient-speciﬁc, noninteractive interventions, and 66 described patient-speciﬁc interactive interventions. Figure 2 shows a bubble plot of the number of
articles for each intervention category published each year.
During the past 5 years, interactive interventions were investigated more frequently than noninteractive initiatives, possibly
because of the increased availability of mobile Internet access and
personal smart devices. Fourteen articles were identiﬁed that
investigated patients’ and clinicians’ perceptions of digital
interventions.
Table II lists the number of studies reporting positive effects
on outcomes for different intervention types.
Generalized studies
There were 17 generalized interventions, eight of which
employed reminders or automated phone calls for medication
doses or pharmacy ﬁlls, and nine that provided asthma education
or asthma management motivation (n ¼ 9). Most were randomized (n ¼ 12) and most had an intervention period of 3 or
more months (n ¼ 15) (Table III).
Six of the studies described a change in adherence with the
intervention; all of these reported a positive effect (6 positive vs
0 no effect or negative). Adherence in these studies was measured
using both subjective (n ¼ 3) and objective (n ¼ 3) approaches.
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TABLE II. Outcomes reporting for intervention categories and types
Adherence
Intervention

Generalized studies
Reminders and pharmacy ﬁll
EM
Patient-speciﬁc, noninteractive, unidirectional
Decision support
Digital questionnaire
Device monitoring
EM
Inhaler only
Inhaler platform
Platform only
Patient-speciﬁc interactive, bidirectional
EM
Inhaler only*
Inhaler platform
Platform only
Telemedicine
Device monitoring

Asthma impairment

Health care use

Articles, n

Positive

No effect

Positive

No effect

Positive

No effect

17
8
9
24
1
9
8
2
2
1
1
66
2
2
14
32
14
2

6
6
0
2
0
0
0
1
1
0
0
17
0
1
5
9
2
0

0
0
0
4
0
1
1
1
0
0
1
8
1
0
0
6
1
0

3
0
3
2
1
1
0
0
0
0
0
31
1
1
5
15
8
1

7
5
2
4
0
1
1
0
1
0
1
15
1
0
2
9
3
0

0
0
0
0
0
0
0
0
0
0
0
12
0
0
3
5
4
0

5
3
2
2
0
1
0
0
0
0
1
14
1
1
0
8
3
1

EM, education and/or motivation.
*The study by Chan et al11 was not included in positive/negative calculations because it was the same study as Chan et al.12

Few studies of generalized interventions reported a positive
effect on asthma impairment (3 positive vs 7 no effect or negative), and none reported meaningful improvements in health care
use (0 positive vs 5 no effect or negative) (Table II and Figure 3).

Patient-specific,
noninteractive,
unidirectional
interventions
Of the 24 studies using patient-speciﬁc, noninteractive, unidirectional interventions, most focused on either digital
questionnaire-based studies (n ¼ 9) or device monitoring studies
(without feedback to the patient; n ¼ 8). Thirteen studies were
randomized and 11 were single-arm. Nine interventions lasted
for less than 3 months (Table IV).
Overall, few studies reported positive effects; only two studies
found beneﬁt in each of the adherence and asthma impairment
domains and none reporting improvements in health care use
(Table II and Figure 3). Positive effects on adherence were noted
in one study of education provision and one involving adherence
tracking with an automated reminder call; moreover, positive
effects on asthma impairment resulted from one study involving
a smartphone symptom and ACT diary with additional education and motivation, and one study in which a decision support
algorithm was used to enter patients into different randomized
controlled trials.
Patient-specific
interactive,
bidirectional
interventions
Patient-speciﬁc, bidirectional interactive interventions were
the largest group of interventions (n ¼ 66). Most often, these
entailed an asthma management platform (n ¼ 32), a digital
inhaler combined with an asthma management platform
(n ¼ 14), or a telemedicine-based intervention (n ¼ 14). Most
studies (n ¼ 45) were randomized, and 15 of the interventions

lasted less than 3 months (including two with the study period
not stated) (Table V).
Reported positive effects outweighed no effect for both
adherence (17 vs 8 studies, respectively) and asthma impairment
(31 vs 15 studies, respectively) (Table II and Figure 3). Adherence was measured subjectively (n ¼ 18) and objectively
(n ¼ 14) in a similar number of studies. Twelve studies found
reductions in health care use, although a similar number
(n ¼ 14) found no effect.
This was the only intervention category within which improvements in both adherence and asthma impairment were
reported more often than not and were seen consistently across
the three most-studied intervention types.

Acceptability and feasibility of interventions
When reported, all types of digital interventions were
considered to be acceptable or favorable to patients or their
caregivers and feasible to implement, although this aspect was
not rigorously investigated in articles reporting intervention reDigital
sults.13,14,16-19,22-24,26,28,43,56,87,105,108,109,111,115,117
inhaler
systems
were
described
as
feasible
to
and
acceptable
to
most
implement31,61,62,65,69-71
patients.11,31,61,70,118 Similarly, digital asthma management
platforms were reported to be both feasible52,57,82,84,93,119 and
acceptable.75,76,92,96,100-102,107 One study reported low use of a
Web portal that was not speciﬁcally targeted to symptomatic
asthma patients.81
Although patients were generally satisﬁed with digital devices
and were willing to use them, alerts were sometimes perceived as
unwelcome if they were received at inopportune times.35 Noninhaler devices (including Fitbits (Google LLC, San Francisco,
CA) to track activity levels and sleep, and devices designed to
assess lung function) were also considered acceptable by
patients.35,52,54

Intervention
type

Intervention
details

Study
period

Effect on ICS adherence with
intervention

Adults only

4510

NS

Reminder

Reﬁll

SA

2y

14

Adolescent or
younger

1187

NS

Reminder

Reﬁll

R

24 mo

15

Adults only

100

NS

Reminder

SMS reminder

SA

5y

e

16

Adolescents
and adults

64

NS

Reminder

SMS reminder

R

6 mo

17

Adolescent or
younger

89

NS

Reminder

R

3 wk

18

Adults only

26

Reminder

R

12 wk

19

Adolescents
and adults

12

Mild,
moderate,
severe
NS

SMS reminder
plus static
education
SMS reminder

2.75% increase in adherence
each month, but
improvements were not
sustained
Signiﬁcant improvement in
self-reported 7-d adherence

Reminder

SMS reminder

R

20

Adults only

8517

NS

Reminder

Reﬁll

21

Adolescent or
younger

359

NS

EM

22

Adults only

655

NS

EM

23

Adults only

150

NS

EM

Static education to
prompt
physician
questioning
Static education
by DVD for
breathing
retraining
SMS education

24

Adolescent or
younger

64

NS

EM

25

Adults only

330

NS

EM

Signiﬁcant but small
improvement
Signiﬁcant improvement in
ICS adherence at 24 mo

Effect on asthma impairment
or symptoms with
intervention

e
e

No difference in ACT scores
between groups
No signiﬁcant difference
between arms

Effect on health care use and/
or hospitalization with
intervention

No change in ED visits or
hospitalizations
No difference in ED visits,
primary care visits or
hospitalizations
e
ED visits and hospitalizations
for asthma were rare

No signiﬁcant change in ACT

e

Signiﬁcant increase vs control

e

e

3 mo

e

e

R

18 mo

R

1y

Modest but signiﬁcant
increase in ICS adherence
e

No signiﬁcant change in mean
self-reported asthma
control
No signiﬁcant change in
asthma control
e

R

12 mo

e

R

13 mo

e

e

R

3 mo

e

Signiﬁcant increase in cACT

R

12 mo

e

No statistically signiﬁcant
change in ACQ scores

No signiﬁcant improvement
in symptom scores

No signiﬁcant effect on acute
asthma health care use
e

e

No signiﬁcant difference in
incidence of ED visits
between groups
e

No signiﬁcant change in ED
or non-emergency health
care professional visits
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Static EM,
updated at
intervals
Static education to
encourage
written asthma
plan use

Study
type

MOSNAIM ET AL

n

Asthma
severity

Reference

Patient age
group

2382

TABLE III. Generalized studies
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EM
NS
29

51

EM
NS
50

Adolescent or
younger
Adults only
28

(c)ACT, (childhood) Asthma Control Test; ACQ, Asthma Control Questionnaire; ED, emergency department; EM, education and/or motivation; ICS, inhaled corticosteroid; SA, single-arm; NS, not speciﬁed; R, randomized; SMS, short
message service.

e
Signiﬁcant improvements in
self-reported asthma
symptoms and control
R

3 months

e

e
e
SA

2 wk

e

e
e
e
1y
SA
EM
NS
34
Adults only
27

26

NS
144
Adults only

EM

Static video
education
during face-toface visits
Static Web-based
education
Static Web-based
education
Static Web-based
education

SA

1 mo

e

Signiﬁcant improvement in
ACT score

e
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Cost-effectiveness
Only one112 of the ﬁve studies to comment on costeffectiveness13,22,109,112,116 found that the digital intervention
was not cost-effective, although formal investigations of costeffectiveness were not performed. A smart nebulizer system was
associated with decreased costs of additional treatments associated with asthma, such as antibiotics and corticosteroids.64
Web-based monitoring of asthma control was deemed likely to
be cost-effective after an analysis of an economic model.39
Perceptions of digital health technology
Fourteen articles commented on perceptions regarding digital
interventions,95,119-131 and all intervention types were widely
considered to be acceptable and useful across groups of patients,
prescribers, and families.
Patients’ uptake of smartphone apps was affected by perceived
need (ie, favorable if asthma not considered to be wellcontrolled)125; for smartphone app uptake in general, ease of access
(ie, downloading) was considered important. Although social media
could attract many initial downloads, long-term engagement was
more successful with face-to-face recruitment by practices.124
Adolescents thought that smartphone apps should be designed
to be visually simple, easy to use, informative, and customizable,
and include familiar components (eg, alerts that appeared and
sounded like their usual messaging apps), and they were open to
using apps for support and information.121,122,130,131 They
preferred time-based to event-based reminders44 and favored
video and peer-chat functionality in addition to medication reminders.119 They were also sensitive to design choices that were
too childish for their age range, but appreciated gamiﬁcation of
asthma management.121-123
Adolescent patients and pharmacists had a positive attitude
toward interactive mobile health interventions,119 and adults and
adolescents were receptive toward educational and directive SMS
messaging; adolescents were also in favor of sending messages to a
support person (ie, parent or guardian).125 Tablet- and
smartphone-based asthma questionnaires were acceptable to patients and useful in certain situations (eg, when HCP time was
limited, or in rural areas).126 Patients and caregivers were supportive of interactive Web-based education provision based on
patient information and preferences, and of augmented reality
inhaler technique training.128
Patients considered that smart devices and inhalers should be
easy to use and convenient in terms of size and portability.95,127
Clinicians valued the concept of intervisit improvement of
adherence and lung function data and considered adherence data
to be especially important, with a preference for ICS adherence
data. Rescue inhaler information was considered valuable to access if patients were overusing them, because this could indicate a
need to adjust the ICS regimen. The opportunity to use a patient’s data to illustrate how adherence affected symptoms or
impairment during consultations was also appreciated.120
Some interesting concerns for clinicians included liability for
acting on real-time data collection between visits when they
could not respond, a preference to see data only before patient
visits, and validation of data accuracy and security when devices
could be shared.120,132
DISCUSSION
In this scoping review, we surveyed a wide variety of approaches to implementing digital technology to improve patient
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Positive

A 10

No effect

Generalized studies (n=17)

No. articles

8

6

4

2

0
Adherence

B

10

Asthma impairment

Healthcare utilization

Patient-specific, non-interactive, unidirectional (n=24)

No. articles

8

6

4

2

0
Adherence

C

Asthma impairment

Healthcare utilization

Patient-specific, interactive, bidirectional (n=66)

40

No. articles

30

20

10

0
Adherence

Asthma impairment

Healthcare utilization

FIGURE 3. Balance of articles reporting positive effect versus no effect on adherence, asthma impairment, and health care use:
A Generalized studies (n ¼ 17). B Patient-specific, noninteractive, unidirectional interventions (n ¼ 24). C Patient-specific interactive,
bidirectional interventions (n ¼ 66).

outcomes from asthma therapy. Such interventions usually focus
on improving patient’s adherence to their treatment regimen,
through dose and prescription-ﬁll reminder systems, behavior
change as a result of education and motivation, or increased
access to health care professionals and asthma advice through
telemedicine or interactive asthma management platforms. We
considered the interventions identiﬁed by our literature search
based on their interactivity with patients, and whether data

communication was unidirectional (data sent either from or to
the patient) or bidirectional (data received from the patient
prompting a response from the intervention). In terms of study
outcomes, we looked for evidence of improvement with the
various interventions in terms of patients’ adherence to ICS
regimens, improvements in impairment owing to asthma, and
improvements in health care use (by reductions in unplanned or
emergency consultations).

Reference

Patient age
group

n

Asthma
severity

Intervention type

Intervention details

Study
type

Study
period

Effect on ICS adherence with
intervention

Adolescent or
younger

1143

NS

Decision support Computerized randomized
controlled trial decision
support

R

16 wk

Change in adherence during therapy
not reported

31

Adolescent or
younger

41

NS

Device
monitoring

Propeller Health platform
only for data collection

R

30 d

Similar average daily adherence
between intervention and control
groups

32

Adults only

239

Severe

Device
monitoring

SA

3 mo

Change in adherence during therapy
not reported

33

Adults only

184

NS

Device
monitoring

INCA adherence and inhaler
technique only for data
collection
INCA adherence and inhaler
technique for periodic
assessment

R

3 mo

34

Adults only

200

NS

2 mo

Adolescent or
younger

32

NS

SA

3 wk

e

36

Adults only

111

NS

Device
monitoring

Smart spirometer only for
data collection
PEFR monitoring by SMS
and digital peak ﬂow
meter, cold symptom
monitoring by SMS
Adherence monitor only for
data collection

SA

35

Device
monitoring
Device
monitoring

Change in adherence during therapy
not reported; adherence via dose
counter was signiﬁcantly lower
than by objective monitoring
e

R

24 wk

37

Adolescent or
younger

90

NS

Device
monitoring

Adherence monitor only for
data collection

SA

3 mo

38

Adults only

123

NS

Device
monitoring

INCA adherence and inhaler
technique only for data
collection

SA

2-4 wk

39

Adolescent or
younger

272

NS

Digital
questionnaire

Cost-effectiveness data for Lv
et al23; Web-based ACT
used to adjust treatment
periodically

R

4 mo

Effect on health
care use and/or
hospitalization
with intervention

Signiﬁcant increase in
proportion of
participants gaining
good control
Mean change in cACT
similar between
intervention and
control groups
e

e

Adherence was
predictive of
asthma
exacerbations
e
e

Change in adherence during therapy
e
not reported; consistent
overestimation of self-reported
adherence vs digitally monitored
Change in adherence during therapy
e
not reported, ethnicity correlated
with adherence
Overall change in adherence during
e
therapy not reported; signiﬁcant
correlation between adherence and
socioeconomic class, education.
Inclusion of inhaler technique
errors signiﬁcantly reduced
adherence by dose counter
e
ACT used to adjust
treatment

e

e

e

e
e

e

e

e

e

MOSNAIM ET AL

30

Effect on asthma
impairment or
symptoms with
intervention
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TABLE IV. Patient-specific, noninteractive, unidirectional interventions
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Patient age
group

n

Asthma
severity

Intervention type

Intervention details

Study
type

Study
period

Effect on ICS adherence with
intervention

Effect on health
care use and/or
hospitalization
with intervention

No signiﬁcant
differences
between groups
in
hospitalizations
or steroid
courses
High cough counts
were associated
with higher use
of health care
services,
hospitalizations,
and ofﬁce visits
e

Adolescent or
younger

272

NS

Digital
questionnaire

See also Beerthuizen et al39;
Web-based ACT used to
adjust treatment
periodically

R

1y

e

No signiﬁcant change
in ACT in Web
intervention group

41

Adolescent or
younger

84

NS

Digital
questionnaire

ADAM iPod cough
monitoring and smartphone
asthma diary for data
collection only

SA

7d

e

e

42

Adolescent or
younger

53

NS

Digital
questionnaire

Automated telephone EMA

SA

1 mo

Change in adherence during therapy
not reported

43

Adolescents
and adults

410

NS

Digital
questionnaire

ACT by SMS

R

5  1 wk

e

44

Adults only

16

NS

Digital
questionnaire

EMA by SMS with automated
prompts for data collection

SA

2 wk

Change in adherence during therapy
not reported

45

Adolescent or
younger

228

NS

Digital
questionnaire

Web-based symptom diary for
data collection only

R

4 wk

Change in adherence during therapy
not reported

46

Adolescent or
younger

50

Moderate

Digital
questionnaire

Smartphone app symptom
diary plus EM

R

3 mo

47

All ages

6 mo

Adolescent or
younger
Adolescents
and adults

Regular data surveys from
asthma patients
Individualized static
education
Tailored static EM

SA

48

7593 Mild, moderate, Digital
severe
questionnaire
68
NS
EM

No signiﬁcant difference in selfreported medication adherence
between groups with additional
education/motivation
Change during study not reported

Change in ACT
during therapy not
reported
Signiﬁcant
improvements in
ACT were
detectable using
SMS reporting
Change in symptoms
during therapy not
reported
Change in ACT and
cACT score during
therapy not
reported
Signiﬁcant
improvement in
cACT

R

13 wk

R

9 mo

49

216

NS

EM

Change during study
not reported
No signiﬁcant difference in adherence
e
at wk 5 and 10
Signiﬁcant improvement in
e
adherence but less than clinically
relevant level

e

e

e

e

e
e
e
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TABLE IV. (Continued)
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Adults only
53

(c)ACT, (childhood) Asthma Control Test; EM, education/motivation; EMA, ecological momentary association; HCP, health care professional; ICS, inhaled corticosteroid; PEFR, peak expiratory ﬂow rate; SA, single-arm; NS, not speciﬁed;
R, randomized; SMS, short message service.

R
WeChat platform with
education and HCP
interaction
Platform only
NS

Inhaler platform
NS
82
Adolescent or
younger
52

67

SA

R

Automated interactive call
plus electronic dose tracker
kHealth platform and digital
phenotyping:
unidirectional; data
available only to HCP
Inhaler only
NS
Adults only
51

50

Adolescent or
younger
50

81

NS

Inhaler only

Adherence monitor for data
collection only

SA

12 mo

e
Change in adherence during therapy Asthma control during
not reported; median adherence
12-mo study period
was 87% and relatively constant in
was high and lung
most patients
function was
normal
10 wk
32% improvement in adherence over No difference in ACT
e
10 wk
Effect of intervention
e
1 or 3 mo Effect of intervention on controller
on ACT during
adherence during study not
reported; poor adherence
study not reported;
poor adherence
associated with poor asthma
control
associated with
poor asthma control
3 mo
No signiﬁcant difference in
No signiﬁcant
No signiﬁcant
medication adherence between
difference in
difference
groups
improvement of
between groups
asthma control
between
intervention and
control groups
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Generalized dose and prescription reminders and nonpersonalized education and motivation were effective in
improving adherence, but not impairment owing to asthma.
Although subjective measurement of adherence is thought to
overestimate adherence compared with objective measurement,33,36 both types of adherence measurement were employed
across these generalized studies; it is possible that adherence
improvements were not sustained long enough to make a
meaningful impact on asthma impairment. The patient-speciﬁc,
noninteractive interventions included several different intervention types, but few reported positive impacts on either adherence
or asthma impairment. However, the most-studied category of
intervention, patient-speciﬁc interactive bidirectional interventions, reported the greatest number of improvements in
adherence and asthma impairment. These beneﬁts were largely
found in studies of the most interactive interventions, those
using interactive telemedicine, or those using an interactive
management platform, with or without a digital inhaler. Each of
these intervention types provides a high level of interactivity and
instant feedback for patients through either live HCP consultation (telemedicine) or responses to monitored data or questionnaires (digital platforms with or without digital inhalers).
Correlating patients’ own asthma experiences (through ACT
scores or other measured parameters) with their asthma management behaviors (eg, ICS adherence, trigger avoidance) may be
a powerful engagement tool to motivate and educate patients
about the need to stay on top of managing their condition.
We were able to identify broad trends in adherence and
changes in asthma impairment among different intervention
categories. The included studies generally did not ﬁnd differences
in health care use with interventions, either because it was not
studied or because the incidence of emergency department visits
or other unscheduled consultations was generally low.
All types of digital health interventions were well-received and
acceptable to patients, caregivers, and clinicians. It is intuitive to
think that digital interventions would be easily scalable to large
populations and therefore be cost-effective, but currently there
are few formal cost-effectiveness studies to conﬁrm this
assumption. In particular, the translation of improved adherence
to improved symptom control and reduced health care use is not
guaranteed, although several studies noted reductions in reliever
or oral steroid use and reductions in unscheduled primary care
visits. There may also be difﬁculties in transitioning coding and
billing practices to accommodate digital interventions.
The progression of digital health monitoring and associated
interventions in asthma still faces signiﬁcant challenges. It is clear
that a successful intervention must be able to combine objective
monitoring with active patient engagement and education or
motivation to maintain behaviors helpful to asthma therapy, and
we have yet to develop an ideal system in this respect. Although
there is further opportunity to incorporate digital interventions
into patient care with respect to linking to patients’ electronic
health records and using data monitoring to trigger further HCP
interventions, there is also the possibility of providing regular
patient support through education about inhaler technique,
avoidance of asthma triggers, and environmental monitoring and
advice (eg, warnings related to high pollen count or air pollution),
which could be equally important in reducing asthma burden.
The extensive implementation of digital interventions is
attractive from the perspective of real-time population health
monitoring as well as the increased opportunity and ability to

Effect on ICS adherence with
intervention

SA

1 mo

e

e

R

6 mo

e

Signiﬁcant improvement in
asthma control

SA

6 wk

e

R

3 mo

Signiﬁcant increase in mean
ACT score (greater than
MID) at 3 mo after
intervention
No signiﬁcant difference in
ACQ between groups

Reliability data for
Chan et al12;
Adherence monitor
with or without
reminders
See also Chan et al11;
adherence monitor
with or without
reminders

R

Not stated

e

R

6 mo

Inhaler
platform

Adherence monitor
and AMP platform

R

3 mo

NS

Inhaler
platform

Propeller Health
platform
monitoring of
SABA use

R

12 mo

Signiﬁcant improvement in
adherence with the reminder
function in poorly adherent
population at baseline; adherence
then decline over 6 mo
Baseline adherence and adherence
vs control not reported. Slight
reduction in adherence in
intervention group during study
e

NS

Inhaler
platform

Adherence monitor
with periodic
feedback

R

12 mo

Patient age group

n

Asthma
severity

Intervention
type

54

Adolescent or
younger

22

NS

Device
monitoring

55

Adults only

72

All

Device
monitoring

56

Adults only

44

NS

EM

57

Adults only

51

Mod

EM

11

Adolescent or
younger

220

NS

Inhaler only

12

Adolescent or
younger

220

NS

Inhaler only

58

Adults only

39

NS

59

All ages

495

60

Adolescent or
younger

77

Intervention details

Vortex whistle and
smartphone app for
PEV
FEV measurement
with smartphone
asthma monitoring
app
Individualized
education in
response to
assignments
Interactive website for
education and
improving
adherence

No signiﬁcant difference between
groups

Signiﬁcantly higher adherence in
intervention group over 12 mo

Signiﬁcant perceived and
objective improvement in
asthma control in
conjunction with Chen
et al90
Signiﬁcant improvement in
cACT vs control

e

No signiﬁcant
differences in
unscheduled health
care visits
e

No signiﬁcant
difference between
groups in HCP
contact or steroid
prescriptions
e

No difference in
frequency of ED
visits

e
Greater improvement from
baseline to 3 mo for
intervention compared with
control group
e
Signiﬁcant improvements in
ACT in initially
uncontrolled adults only;
signiﬁcantly larger
decrease in SABA use vs
routine care
No signiﬁcant difference in
Signiﬁcantly fewer
improvement of asthma
hospital admissions
control between
in intervention
intervention and control
group
groups
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TABLE V. Patient-specific interactive, bidirectional interventions

Adolescent or
younger

14

Moderate to
severe

Inhaler
platform

62

Adolescent or
younger
All ages

7

NS

224

NS

Inhaler
platform
Inhaler
platform

63

Adherence monitor
with motivational
interviewing and
feedback
Adherence monitor
and smartphone app
Propeller Health
platform
monitoring of
SABA and ICS use

SA

3 mo

Change in adherence during therapy
not reported

Borderline signiﬁcant
improvement in ACT (P ¼
.05)

e

SA

12 wk

e

e

SA

1y

Not performed owing to low patient
numbers
e

e

12 wk

Signiﬁcant reduction
in asthma-related
ED visits, and
combined ED and
hospitalization
events
Signiﬁcantly lower
frequency of ED
visits, respiratory
infections,
antibiotics or
systemic steroid
use, and therapeutic
cost vs control
e

Adolescent or
younger

65

NS

Inhaler
platform

Smart nebulizer with
smartphone app for
HCP contact

R

65

Adolescent or
younger

12

NS

Inhaler
platform

SA

66

Adults only

30

NS

Inhaler
platform

67

Adolescents and
adults

120

NS

Inhaler
platform

68

Adolescent or
younger

12

NS

Inhaler
platform

Adherence monitor
with smartphone
app
Adherence monitor
for SABA use and
interactive Web
interface
Adherence monitor
for SABA use and
interactive Web
interface
Adherence monitor
and smartphone app

69

Adolescents and
adults

143

Moderate to
severe

Inhaler
platform

70

Adults only

32

NS

Inhaler
platform

71

All ages

497

NS

Inhaler
platform

Statistically signiﬁcantly higher
adherence at all time points vs
control

Not stated Clinically signiﬁcant improvement
during pilot study

e

e

SA

4 mo

e

SA

1 mo

Rescue medication monitored rather
than ICS

SA

8 wk

Adherence monitor
and Web interface

R

6 mo

Adherence monitor
for data collection
with customizable
reminders
Adherence monitor
with interactive
smartphone app

SA

3 wk

Patients meeting target ICS adherence 58% of patients reached MID
(50%) increased from 8% to 58%
for ACT scores
at wk 8
Signiﬁcant increase in adherence in No signiﬁcant difference in
groups receiving reminders and
ACT between groups
feedback
Change in adherence during therapy
e
not reported

SA

12 mo

Rescue medication monitored rather
than ICS

Small but statistically
signiﬁcant improvement in
ACT scores

e

Signiﬁcant reduction in
SABA use during study

e

Signiﬁcant increase in
symptom-free days over 12
mo

e

e

e

e
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61

Asthma
severity

Intervention
type

Study
period

Adults only

138

NS

Platform only

breathe mobile health
platform

R

12 mo

73

Adults only

408

NS

Platform only

Online asthma care
tool

R

12 mo

74

Adults only

60

NS

Platform only

SA

4 mo

100

NS

Platform only

R

6 mo

e

ACT evaluated but not
reported separately

Adults only

327

All

Platform only

Interactive
smartphone app
Online MAP asthma
educational and
monitoring portal
POPET interactive
smartphone app

75

Adults only

76

R

6 mo

e

Signiﬁcant improvements in
ACT and proportion of
well-controlled patients

77

Adolescent or
younger

152

Mild to
moderate

Platform only

Asthma management
smartphone app

R

12 mo

78

Adolescent or
younger

193

NS

Platform only

AsthmaCare
smartphone asthma
management app

R

6 mo

e

79

Adolescent or
younger

34

NS

Platform only

Smartphone AMP

R

6 mo

e

80

Adults only

103

NS

Platform only

R

9 wk

81

Adolescent or
younger

237

All

Platform only

Online asthma patient
community
MyAsthma online
asthma
management portal

R

12 mo

Signiﬁcant increase in asthma
medication changes or reﬁlls for
children with uncontrolled asthma
after parental use of portal

e

82

Adults only

44

NS

Platform only

snuCare smartphone
AMP and PFM

R

8 wk

Signiﬁcant improvement in
adherence

e

Patient age group

72

Intervention details

Effect on ICS adherence with
intervention

Self-reported controller use increased Post hoc analysis associated
e
before clinic visits
high ACT scores with app
use
No signiﬁcant difference between
Signiﬁcant improvement in
No signiﬁcant
groups
total ACT score with
difference between
intervention
groups
e
Signiﬁcant increase in ACT
e

Statistically signiﬁcant higher
treatment adherence vs control
group

Statistically signiﬁcantly
higher cACT scores and
fewer exacerbations vs
control
e

Overall, no changes in ACT
and self-efﬁcacy scores
between groups;
adolescents with
uncontrolled asthma had
improved ACT within
intervention group
No change in self-reported adherence
e

No signiﬁcant
difference in
hospitalizations
Signiﬁcant reduction
in unplanned
hospital visits and
ED visits
e

Signiﬁcant reduction
in urgent care visits,
but not ED visits or
hospitalizations
e

e
Signiﬁcantly more
medication changes
and primary care
asthma visits with
portal use
e
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TABLE V. (Continued)

48

NS

Platform only

Interactive
motivational
interviewing and
EMA
Interactive
smartphone app

R

3 mo

Trend for fewer doses missed vs
control, but not statistically
signiﬁcant

84

Adolescent or
younger

58

NS

Platform only

R

6 mo

SA

8 wk

Signiﬁcant improvement in patients
with low (<75%) baseline
adherence
e

85

Adolescent or
younger

20

NS

Platform only

Smartphone AMP

86

Adults only

21

Moderate to
severe

Platform only

87

Adolescent or
younger

26

Moderate to
severe

Platform only

Online P’ASMA
asthma
management portal
EM by phone plus
tailored SMS

R

4 wk

No signiﬁcant difference between
groups

R

3 mo

Reduced barriers to adherence

88

Adults only

89

Moderate to
severe

Platform only

Smartphone asthma
diary with
management
feedback
SMS monitoring with
HCP feedback as
necessary
SMS monitoring with
HCP feedback as
necessary

R

6 mo

e

89

Adults only

120

NS

Platform only

R

3 mo

e

90

Adults only

424

NS

Platform only

R

3 mo

e

91

Adults only

80

NS

Platform only

CARAT smartphone
app for asthma
monitoring with email feedback
CHANGE Asthma
smartphone app
with education and
AMP
ADAPT interactive
smartphone app
including CARAT

R

6 mo

92

Adolescent or
younger

40

NS

Platform only

R

4 mo

93

Adolescent or
younger

234

NS

Platform only

R

6 mo

No difference between groups for
medication adherence

e

Signiﬁcant improvement in selfreported adherence patients with
poor baseline adherence with or
without uncontrolled asthma; no
signiﬁcant difference overall

Trend for improved ACT vs
control, but not statistically
signiﬁcant

e

e

No signiﬁcant change
in ED or acute
visits during study
e

Signiﬁcant increase in ACT
for participants with
uncontrolled asthma at
baseline
No signiﬁcant difference
between groups

e

Clinically meaningful
e
improvement in symptoms
with medium to large effect
sizes over 3 mo
Asthma symptom scores used Signiﬁcantly fewer
to adjust therapy
patients with
unscheduled ED
visits
No signiﬁcant difference
No signiﬁcant
between groups
difference between
groups
No signiﬁcant difference
No signiﬁcant
between groups
difference in ED
visits or
hospitalizations
between groups
after 5 wk
No signiﬁcant difference
e
between groups

No signiﬁcant difference in
cACT between groups

e

No signiﬁcant difference in
CARAT score between
groups

e
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n

Asthma
severity

Intervention
type

94

Adolescent or
younger

87

NS

Platform only

95

Adolescent or
younger

15

NS

Platform only

96

Adults only

107

NS

Platform only

97

Adolescent or
younger

24

All

Platform only

98

Adolescent or
younger

90

All

Platform only

99

Adults only

200

Moderate

Platform only

100

Adults only

106

NS

Platform only

101

Adolescent or
younger

24

NS

Platform only

102

Adults only

22

NS

Platform only

103

Adolescents

422

All

Platform only

Intervention details

ADAPT interactive
smartphone app
including CARAT
mASMAA interactive
SMS asthma diary
system
Web platform for
asthma monitoring,
AMP and HCP
contact
Web-based peak ﬂow
and symptom
tracker with
feedback
Web-based peak ﬂow
and symptom
tracker with
education, AMP
and feedback
Web-based peak ﬂow
and symptom
tracker with AMP
and feedback
Web-based AMP with
SMS feedback

AsthmaCare
smartphone asthma
management app
Web-based AMP and
symptom/peak ﬂow
diary with feedback
Web-based platform
with tailored
feedback to
questions

Study
type

Study
period

Effect on ICS adherence with
intervention

R

6 mo

No signiﬁcant change in self-reported Change in CARAT score
adherence
during therapy not reported

SA

2 wk

Anecdotal reports of improved
adherence

R

30 mo

e

SA

2-15 mo

e

R

1y

R

1y

e

R

12 mo

Change in adherence during therapy
not reported

SA

30 d

Increased adherence in 85% of
subjects

SA

8d

Change in adherence during therapy
not reported

R

12 mo

e

No signiﬁcant difference in selfreported medication adherence
between groups

e

Anecdotal reports of
e
improved control over
asthma symptoms
Signiﬁcant and sustained
e
(30 mo) improvement in
asthma control via AQLQ
and ACQ
Signiﬁcant reduction in
Signiﬁcant reduction
number of wheezing
in doctor or clinic
episodes
visits
Signiﬁcant improvement in
ACQ scores but not
sustained beyond 12 mo

e

Signiﬁcant improvement in
ACQ for patients with
partly controlled or
uncontrolled asthma only
No signiﬁcant difference in
ACT between groups

e

e

Signiﬁcant improvement in
CACG symptom
benchmarks
Signiﬁcant reduction in
symptom days

No signiﬁcant
difference in
hospitalizations or
ED visits between
groups
e

No signiﬁcant
difference in urgent
health care visits
No difference in
frequency of ED
visits
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TABLE V. (Continued)

Adults only

51

Moderate to
severe

Telemed

EM by phone plus
static education

SA

9 mo

105

Adolescent or
younger

400

NS

Telemed

106

Adolescent or
younger

210

NS

107

Adults only

100

108

All ages

109

31.4% of 35 subjects indicated
improved adherence

Change in ACT statistically
signiﬁcant, but less than
MID

No difference in ED
visits or
hospitalizations
between baseline
and end of study
Reduced likelihood of
ED visit or
hospitalization for
asthma
No signiﬁcant
difference between
groups

Telemed visits

R

1 school y

e

Signiﬁcant improvement in
symptom-free days per 2
wk

Telemed

Online virtual asthma
clinic

R

16 mo

e

NS

Telemed

Telemed and SMS
asthma monitoring

R

12 mo

e

20

NS

Telemed

Telemed education

SA

1y

e

Adolescent or
younger

210

NS

Telemed

Telemed visits

R

16 mo

e

110

Adolescent or
younger

50

Severe

Telemed

R

12 mo

e

111

Adolescent or
younger

48

NS

Telemed

SA

7 mo

e

e

112

Adults only

422

NS

Telemed

Telemonitoring of
FEV1 and
intervention if
necessary
Telemed evaluation
compared with
face-to-face
Telemed EM

Signiﬁcant improvement in
cACT but not ACT, in
children and adolescents,
respectively
No hospitalizations
Statistically, but not
during study
clinically, signiﬁcant
increase in ACT score for
intervention and control
(between-group interaction
not reported)
Increase in proportion of welle
controlled patients by ACT
score
Signiﬁcant increase in cACT Online asthma
but no difference in ACT
management was
for teenagers, after 16 mo
associated with
fewer outpatient
clinic visits
No signiﬁcant difference
e
between groups for
exacerbations

R

2y

e

Signiﬁcantly improved ACT
scores after 2 y

113

Adolescent or
younger

362

NS

Telemed

Telemed EM

R

1y

e
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e
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Signiﬁcant reduction
in asthma-related
hospitalization
Signiﬁcant reduction in
Urgent care events
proportion of children with
decreased in both
poorly controlled asthma
groups with no
signiﬁcant
difference between
groups
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Within-group improvement in
adherence in intervention group
3 mo
R
Telemed education
Telemed
NS
Adults only
117

98

Adolescent or
younger
116

AMP, asthma management plan; (c)ACT, (childhood) Asthma Control Test; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; EM, education or motivation; EMA, ecological momentary association; FEV,
forced expiratory volume; HCP, health care professional; ICS, inhaled corticosteroid; MID, minimal important difference; PEFR, peak expiratory ﬂow rate; PEV, peak expiratory volume; SA, single-arm; NS, not speciﬁed; R, randomized;
SABA, short-acting b-agonist; SMS, short message service; Telemed, telemedicine intervention.

Signiﬁcant reduction
in ED visits and
hospitalizations
during follow-up
No signiﬁcant between-group
e
difference in ACT; withingroup improvement in
intervention group

e
1y
R

Adults only
115

295

NS

Telemed

2 wk
SA

Adolescent or
younger
114

30

NS

Telemed

Telemed education
and inhaler
technique
Telemed education

e

e

No statistically signiﬁcant
difference between groups
in reported symptom-free
days
e
Signiﬁcant increase in caregiverreported adherence but no
signiﬁcant difference in asthma
medication ratio
e
R

Patient age group

393

NS

Telemed

Telemed EM

6 mo
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Intervention
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Intervention details

Study
type

Study
period

Effect on ICS adherence with
intervention

Effect on asthma impairment
or symptoms with
intervention
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improve individual asthma outcomes through treatment
personalization and daily disease management. Data analysis may
also assist the understanding of relations and causal mechanisms
among patient characteristics, environment, and asthma symptoms and exacerbations, ultimately leading to the development of
patient digital phenotypes.
However, beyond the challenge of developing suitable technologies, considerable ﬁnancial, technological, and political
barriers still need to be overcome. The development of artiﬁcial
intelligence protocols to interpret and apply the huge amount of
monitoring data involved will be important. There will also be a
considerable emphasis on the infrastructure necessary to incorporate continuous monitoring into patients’ overall health care to
support physicians. Such a fundamental change in the organization and delivery of health care will also have signiﬁcant effects
on liability for physicians making artiﬁcial intelligenceaugmented decisions.133,134 Large-scale personal health data
collection naturally generates concern regarding data security and
use, and patients and physicians must be conﬁdent about how
their data will be used, who will have access to it, and the extent
to which individual patients will own their data.135
Regardless of pharmacological therapy, consultations can
already be implemented regularly by videoconference, which is
especially important for patients with reduced mobility or
reduced free time, or in remote locations; videoconferencing
could also be used to provide support between face-to-face appointments. In the context of a pandemic such as COVID-19,
reducing face-to-face contact between clinicians and selected
patients has been a necessity. The use of telemedicine and video
consultation was implemented as an elegant solution to this
challenge for patient assessment and education, both of which
can be delivered remotely.136,137 One related effect of the current
pandemic situation is a large-scale uptake of videoconference
technology for work and social contact in the general population,
which could help acclimatize patients and physicians to accessing
and providing health care in this way. We consider it likely that
many of the beneﬁts of telemedicine realized during the
pandemic, initially through necessity, will continue to gain
increasing acceptance and form an integral part of respiratory
care in the future.137,138

Limitations
Conclusions from this scoping review are limited by heterogeneity in terms of the wide variety of study designs and
outcome measures and the different ways of implementing
similar interventions for patient-independent and patientdependent initiatives. In addition, study heterogeneity limited
our interpretation of different outcomes for the same intervention category (eg, the changes observed in adherence were
not necessarily measured in the same studies as changes in
ACT). The ACT was the most common measure of asthma
burden and is a subjective measure of patients’ perception of
impairment resulting from asthma, rather than a measure of
risk for an asthma exacerbation. Changes in asthma exacerbations were not commonly used as a primary outcome measure,
possibly because the expected number of exacerbations in study
populations was not sufﬁciently frequent to make this a useful
end point.
Because patients were generally monitored for no more than
12 months (and commonly only 3 or 6 months), the long-term
effects of the various interventions are unknown. Studies also
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typically did not account for seasonality or incorporate environmental information (such as aeroallergen or air pollution
levels). Most of the studies analyzed did not specify participants’
asthma severity at baseline and lacked stratiﬁcation by asthma
severity. An abundance of studies also reported outcomes only at
single speciﬁc time points or as a single assessment for the whole
study period, rather than as change over time associated with a
speciﬁc intervention.
The relation between asthma controller adherence and health
care use is an important issue, but one that is challenging to
study. In addition to the acknowledged problems with the accuracy of self-reported adherence,48,139,140 in a general population of treated asthma patients who are not under close clinical
supervision, it would be expected that the frequency of emergency or unplanned clinical consultation would be low, and
therefore statistically signiﬁcant changes would be difﬁcult to
detect. The studies identiﬁed for this review rarely assessed health
care use systematically, and few reported on both adherence and
health care use. Furthermore, correlating changes in adherence
with changes in use outcomes is confounded by several patientrelated and sociobehavioral factors including symptom severity,
ethnicity, level of educational achievement, household income,
and attitude toward treatment.141
Therefore, the fact that reductions in health care use were not
reported with digital asthma interventions in the studies discussed in this review does not mean that these interventions are
not associated with beneﬁt in terms of health care resource use in
the real world. The patient populations, intervention assessments, and data collection methods might not have been capable
of detecting health care use changes accurately, even where these
may have occurred. Further research into the effects of adherence
on health care use is undoubtedly needed, and considerable effort
will be required to account for these factors in the design of
future studies assessing digital interventions. Furthermore, future
research into digital technology as a part of asthma interventions
would beneﬁt from a convention on standard approaches to
outcomes and their measurement to enhance similarity in the
ways in which we assess asthma treatment.

CONCLUSIONS
Digital health interventions are acceptable to asthma patients
and clinicians, and the relative ubiquity of mobile Internet- and
Bluetooth-connected devices in everyday life makes real-time
monitoring of asthma treatment and symptoms extremely
feasible. However, an effective digital intervention must fulﬁll
several important design criteria. Both inhaler devices and software should be intuitive and easy to use, and hardware should be
unobtrusive with accurate and objective measurement of adherence and other parameters, and be seamlessly integrated with
software providing convenient assessment of symptoms and
asthma control. Software should be designed to educate and
maintain patients’ engagement (at a variety of different ages),
provide clear communication of hardware- and softwaremeasured parameters for access by patients and clinicians, and
be customizable by patients to ﬁt into their lives and routines.
Motivating patients to take an active role in managing their
condition and maintaining their interest in doing so is of
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paramount importance in designing a successful future digital
intervention.
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